



Asep Medical Holdings Inc.

## Asep Medical Holdings Announces up to C\$1,165,000 LIFE Offering

**March 3, 2026** — **Vancouver, British Columbia** – Asep Medical Holdings Inc. (“**Asep**” or the “**Company**”) (CSE: ASEP; OTCQB: SEPSF; FSE: JJ8) announces that it intends to complete an offering consisting of up to 5,547,619 units of the Company (“**Units**”) at a price of C\$0.21 per Unit, to raise aggregate gross proceeds up to C\$1,165,000 (the “**Offering**”). Each Unit will be comprised of one common share in the authorized share structure of the Company (a “**Share**”) and one Share purchase warrant (a “**Warrant**”). Each Warrant will be subject to a 60-day hold period and will entitle the holder thereof to purchase one Share at an exercise price of C\$0.28 for 36 months following the completion of the Offering.

The Units to be issued under the Offering will be offered to purchasers pursuant to the listed issuer financing exemption (“**LIFE Exemption**”) under Part 5A.2 of National Instrument 45-106 – *Prospectus Exemptions* as amended by the Canadian Securities Administrator’s Coordinated Blanket Order 45-935 – *Exemption from Certain Conditions of the Listed Issuer Financing Exemption*, in all the provinces of Canada, except Québec. The Units offered under the LIFE Exemption will not be subject to resale restrictions pursuant to applicable Canadian securities laws.

There is an offering document (“**Offering Document**”) related to the Offering that can be accessed under the Company’s profile on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca) and on the Company’s website at [www.asepmedical.com](http://www.asepmedical.com). Prospective investors should read the Offering Document before making an investment decision.

The Company plans to use the net proceeds from the Offering for research and development, repayment of existing debts and general working capital purposes, and as otherwise described in the Offering Document. The Offering is scheduled to close on or about March 31, 2026, and is subject to certain conditions customary for transactions of this nature, including, but not limited to, the receipt of all necessary approvals, including the approval of the Canadian Securities Exchange.

The securities to be offered pursuant to the Offering have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “**U.S. Securities Act**”) or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This news release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.



Asep Medical Holdings Inc.

#### **ABOUT ASEP MEDICAL HOLDINGS INC.**

Asep is a standout biotechnology research and development company based in Victoria, BC, Canada. The Company possesses a valuable portfolio of global patents for innovative diagnostic and therapeutic medical technologies. These technologies were developed over the past decade at the University of British Columbia under the guidance of Dr. Robert E. W. Hancock, one of the world's foremost microbiologists and the CEO of Asep. Asep holds a controlling interest in two private subsidiary companies — Sepset Biosciences (Asep's leading product, a sepsis diagnostic technology) and ABT Innovations (specializing in anti-biofilm technology). As the Company's patented innovations address unmet medical needs, it presents a unique investment opportunity for both retail and institutional investors. It is also an attractive buyout target for a major global pharmaceutical operator.

#### **FOR MORE INFORMATION, PLEASE CONTACT**

Chris Dallin

Asep Medical Holdings Inc.

E. [chris@asepmedical.com](mailto:chris@asepmedical.com)

T. 604-362-3654

#### **FORWARD-LOOKING STATEMENTS**

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plans," "continues," "expects," "projects," "intends," "believes," "estimates," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements include but are not limited to Company's anticipated uses of proceeds from the Offering. Various assumptions were used in drawing conclusions or making the predictions contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management on the date the statements are made and are subject to a variety of risks, including the risk that the Company's products may not perform as expected, may not receive regulatory approvals, or may not generate revenue as anticipated. Additional risk factors are identified in the Asep Medical Holdings Inc. prospectus dated November 9, 2021, and in the Company's management discussion and analysis, available for review under the Company's profile at [www.sedarplus.ca](http://www.sedarplus.ca). Asep Medical Holdings Inc. undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.